{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-056971","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2024-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.425200+00:00","generated_at":"2026-06-02T22:54:10.953176+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Brainstorm Cell receives Nasdaq delisting notice; files appeal to stay trading","bullets":["Received Staff Letter on May 1, 2024 for failing to meet $1.00 minimum bid price by April 29, 2024.","Submitted hearing request to Nasdaq Hearings Panel on May 2, 2024 to appeal delisting determination.","Suspension and Form 25-NSE stayed pending final Panel decision; trading continues under BCLI.","No assurance that Panel will grant an exception or that compliance will be regained."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-056971","json":"https://secwatch.observer/filing/0001104659-24-056971.json","markdown":"https://secwatch.observer/filing/0001104659-24-056971.md","text":"https://secwatch.observer/filing/0001104659-24-056971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924056971/0001104659-24-056971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924056971/tm2413371d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:54:10.953176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0325cb743c56605be5eb10305b088ffc0131e1f1","claim":"BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"May 1, 2024, the Company received a staff determination letter (“Staff Letter”) from the Staff of Nasdaq indicating that the Company had not regained compliance with the Minimum Bid Price Requirement by April 29, 2024. Pursuant to the Nasdaq Listing Rules and the Staff Letter, if the Company does not request an appeal of the Staff’s determination by May 8, 2024, the Company’s securities will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on May 10, 2024, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924056971/0001104659-24-056971-index.htm","confidence":0.97,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}